3,5-Dimethylbenzyl fluoride | 136822-77-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Dimethylbenzyl fluoride
• 英文别名: 1-(Fluoromethyl)-3,5-dimethylbenzene
• CAS: 136822-77-0
• 化学式: C₉H₁₁F
• 分子量: 138.185
• InChiKey: MNMIZHFPFOWROA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  均三甲苯 在 caesium fluoroxysulphate 、 氧气 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 2,4,6-三甲基氟苯 、 3,5-Dimethylbenzyl fluoride
  参考文献：
  名称：

  Mild fluorofunctionalization of side chains in alkyl substituted aromatics by cesium fluoroxysulfate

  摘要：

  DOI：

  10.1021/jo00026a032

文献信息

• FURANYL COMPOUNDS AND THE USE THEREOF
  申请人：NovoMedix, LLC

  公开号：US20140309297A1

  公开（公告）日：2014-10-16

  Provided herein are substituted furanyl compounds, pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate eIF4E activity. In one embodiment, the compounds provided herein modulate the Hedgehog pathway activity. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.

  本文提供了替代呋喃基化合物，包括这些化合物的制药组合物、制备方法和使用方法。这些化合物对于治疗、预防和/或改善各种疾病，包括癌症和增殖性疾病，具有用途。在一个实施例中，本文提供的化合物调节eIF4E活性。在一个实施例中，本文提供的化合物调节Hedgehog通路活性。在一个实施例中，本文提供的化合物与手术、放射治疗、免疫治疗和/或一个或多个其他抗癌药物结合使用，用于治疗、预防和/或改善癌症和增殖性疾病。
• Carboxamide derivative and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090186874A1

  公开（公告）日：2009-07-23

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B and ring C are each an aromatic ring optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), Z is an optionally halogenated C 1-6 alkyl group, Y is a methylene group optionally having substituent(s), m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof. The compound of the present invention has a superior tachykinin receptor antagonistic action, particularly an SP receptor antagonistic action, and is useful as a pharmaceutical agent, for example, a tachykinin receptor antagonist, an agent for the prophylaxis or treatment of an abnormality of lower urinary tract functions, a digestive organ disease or a central nerve disease, and the like.

  本发明涉及一种化合物，其表示为以下式子： 其中，环A是一种含氮杂环，可以选择进一步具有取代基；环B和环C分别是芳香环，可以选择进一步具有取代基；R1是氢原子，一个碳氢基团，可以选择进一步具有取代基，一个酰基基团或一个杂环基团，可以选择进一步具有取代基；Z是一个可选择卤代的C1-6烷基基团，Y是一个可选择具有取代基的亚甲基基团，m和n均为0到5的整数，m+n是2到5的整数，且是单键或双键，或其盐。本发明的化合物具有优异的速激肽受体拮抗作用，特别是SP受体拮抗作用，并且可用作制药剂，例如速激肽受体拮抗剂，预防或治疗下尿路功能异常、消化器官疾病或中枢神经疾病等。
• [EN] RAS INHIBITORS<br/>[FR] INHIBITEURS DE RAS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2022235864A1

  公开（公告）日：2022-11-10

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物、以及其制备的药物组合物和蛋白质复合物，能够抑制Ras蛋白，并将其用于治疗癌症。
• PIPERIDINE DERIVATIVES AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1790636A1

  公开（公告）日：2007-05-30

  The present invention provides a compound represented by the formula: wherein Ar is an aryl group optionally having substituents, R is a C1-6 alkyl group, R1 is a hydrogen atom, a hydrocarbon group optionally having substituents, an acyl group or a heterocyclic group optionally having substituents, X is an oxygen atom or an imino group optionally having substituents, ring A is a piperidine ring optionally further having substituents, and ring B is a benzene ring having substituents, or a salt thereof, and an agent for the prophylaxis or treatment of lower urinary tract abnormality and the like, which contains the compound.

  本发明提供了一种由式表示的化合物： 其中 Ar 是任选具有取代基的芳基，R 是 C1-6 烷基，R1 是氢原子、任选具有取代基的烃基、酰基或任选具有取代基的杂环基，X 是氧原子或任选具有取代基的亚氨基，环 A 是任选进一步具有取代基的哌啶环，环 B 是具有取代基的苯环，或其盐，以及含有该化合物的预防或治疗下尿路异常等疾病的制剂。
• DERIVES DE BENZIMIDAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DE GNRH
  申请人：SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.

  公开号：EP1467974B1

  公开（公告）日：2007-08-15